Emerald Advisers LLC Decreases Holdings in Integer Holdings Co. (NYSE:ITGR)

Emerald Advisers LLC lowered its stake in Integer Holdings Co. (NYSE:ITGR - Free Report) by 56.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 6,450 shares of the medical equipment provider's stock after selling 8,223 shares during the quarter. Emerald Advisers LLC's holdings in Integer were worth $838,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. GSA Capital Partners LLP purchased a new stake in Integer in the 1st quarter worth approximately $786,000. Blue Trust Inc. lifted its stake in Integer by 460.4% in the second quarter. Blue Trust Inc. now owns 5,643 shares of the medical equipment provider's stock worth $658,000 after acquiring an additional 4,636 shares during the period. UniSuper Management Pty Ltd bought a new stake in Integer in the first quarter valued at $976,000. Earnest Partners LLC increased its position in Integer by 3.2% during the 2nd quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider's stock valued at $139,911,000 after purchasing an additional 37,340 shares during the period. Finally, Great Lakes Advisors LLC raised its holdings in Integer by 56.7% in the 2nd quarter. Great Lakes Advisors LLC now owns 45,218 shares of the medical equipment provider's stock worth $5,236,000 after purchasing an additional 16,355 shares in the last quarter. Hedge funds and other institutional investors own 99.29% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ITGR. Truist Financial reduced their price target on shares of Integer from $150.00 to $147.00 and set a "buy" rating on the stock in a research report on Friday, October 25th. Benchmark increased their target price on Integer from $130.00 to $140.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Piper Sandler restated an "overweight" rating and set a $140.00 price target (up from $125.00) on shares of Integer in a research report on Friday, October 25th. Oppenheimer assumed coverage on Integer in a report on Tuesday, July 16th. They issued an "outperform" rating and a $135.00 price objective for the company. Finally, Citigroup boosted their target price on shares of Integer from $124.00 to $130.00 and gave the company a "neutral" rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Integer presently has a consensus rating of "Moderate Buy" and an average target price of $139.75.

Integer Stock Up 0.1 %

Shares of NYSE ITGR traded up $0.08 during trading on Monday, reaching $126.53. The company had a trading volume of 213,877 shares, compared to its average volume of 311,153. The business's 50-day moving average is $128.00 and its 200 day moving average is $121.38. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. The stock has a market cap of $4.24 billion, a PE ratio of 39.03, a P/E/G ratio of 1.78 and a beta of 1.09. Integer Holdings Co. has a 12-month low of $83.69 and a 12-month high of $133.53.

Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, beating analysts' consensus estimates of $1.36 by $0.07. The business had revenue of $431.42 million during the quarter, compared to analyst estimates of $440.59 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. Integer's revenue was up 8.7% compared to the same quarter last year. During the same period last year, the business earned $1.27 EPS. As a group, equities analysts forecast that Integer Holdings Co. will post 5.33 earnings per share for the current fiscal year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.